For example, HDAC6 inhibitor treatment reduced pathological tau hyperphosphorylation and improved cognitive behaviors in mouse models of Alzheimer’s disease [14–16]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.